Jasper Therapeutics Inc. [NASDAQ: JSPR] jumped around 0.16 points on Wednesday, while shares priced at $1.85 at the close of the session, up 9.47%. The company report on January 25, 2023 that Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Credit Suisse Securities (USA) LLC and William Blair & Company, L.L.C. are acting as the active book-running managers for the proposed offering. Oppenheimer & Co. Inc. is acting as a passive book-running manager for the proposed offering.
Jasper Therapeutics Inc. stock is now 283.10% up from its year-to-date (YTD) trading value. JSPR Stock saw the intraday high of $2.00 and lowest of $1.60 per share. The company’s 52-week high price is 5.81, which means current price is +35.04% above from all time high which was touched on 01/03/23.
Compared to the average trading volume of 2.94M shares, JSPR reached a trading volume of 8938886 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Jasper Therapeutics Inc. [JSPR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JSPR shares is $6.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JSPR stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Jasper Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on February 28, 2022. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Outperform. The new note on the price target was released on November 08, 2021, representing the official price target for Jasper Therapeutics Inc. stock.
The Average True Range (ATR) for Jasper Therapeutics Inc. is set at 0.34 The Price to Book ratio for the last quarter was 1.42, with the Price to Cash per share for the same quarter was set at 1.42.
How has JSPR stock performed recently?
Jasper Therapeutics Inc. [JSPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.11. With this latest performance, JSPR shares gained by 293.62% in over the last four-week period, additionally sinking by -3.65% over the last 6 months – not to mention a drop of -58.05% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JSPR stock in for the last two-week period is set at 60.16, with the RSI for the last a single of trading hit 59.38, and the three-weeks RSI is set at 60.11 for Jasper Therapeutics Inc. [JSPR]. The present Moving Average for the last 50 days of trading for this stock 0.9892, while it was recorded at 1.8160 for the last single week of trading, and 1.7429 for the last 200 days.
Jasper Therapeutics Inc. [JSPR]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -39.82, with Return on Assets sitting at -31.38.
Jasper Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.10 and a Current Ratio set at 7.10.
Insider trade positions for Jasper Therapeutics Inc. [JSPR]
There are presently around $38 million, or 61.50% of JSPR stock, in the hands of institutional investors. The top three institutional holders of JSPR stocks are: QIMING U.S. VENTURES MANAGEMENT, LLC with ownership of 5,852,982, which is approximately 0% of the company’s market cap and around 5.90% of the total institutional ownership; ABINGWORTH LLP, holding 5,628,558 shares of the stock with an approximate value of $10.41 million in JSPR stocks shares; and VELAN CAPITAL INVESTMENT MANAGEMENT LP, currently with $5.96 million in JSPR stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Jasper Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 12 institutional holders increased their position in Jasper Therapeutics Inc. [NASDAQ:JSPR] by around 796,939 shares. Additionally, 7 investors decreased positions by around 354,509 shares, while 8 investors held positions by with 19,185,624 shares. The mentioned changes placed institutional holdings at 20,337,072 shares, according to the latest SEC report filing. JSPR stock had 5 new institutional investments in for a total of 341,500 shares, while 4 institutional investors sold positions of 34,002 shares during the same period.